# **Special Issue**

# Design, Synthesis and Evaluation of New Antitumor Agents

## Message from the Guest Editor

In many countries around the world, cancer is the leading cause of death. This is particularly the case in developed countries which have an increasing average age of their populations. Despite great advances in its treatment, with numerous advances in chemotherapy, surgeries and radiation treatments, there are still many cancers which have poor patient prognosis and limited available therapies. There is therefore still a real need to develop new treatments for cancer, especially treatments with fewer side-effects than older classical treatments. In this Special Issue, we wish to focus on all areas related to the development of new anti-tumour agents. This includes the discovery, design, synthesis and biological testing of novel treatments for cancer.

### **Guest Editor**

Prof. Dr. David Barker

School of Chemical Sciences, The University of Auckland, Auckland 1010, New Zealand

### Deadline for manuscript submissions

closed (30 April 2022)



## **Molecules**

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/99846

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/molecules





# **Molecules**

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

### **Editor-in-Chief**

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

